Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

TR: Given the potential benefits, do you think enough companies will regulate voluntarily to make a new law unnecessary?

RD: That remains to be seen. Some of us believe that EPA’s voluntary program should be coupled with a regulation that doesn’t impose any testing requirements, but simply says “tell us what you’re doing.” It insures that EPA gets a full picture of what’s going on. In some ways I think there’s a business argument for this too – that it creates a more level playing field, and companies that do step forward aren’t penalized by being at a disadvantage to companies that are hiding in the weeds.

TR: If a new law proves to be necessary, what should it look like?

RD: I’m certainly not of the view that we know enough right now, even if there was a political will, to lay out prescriptions. It’s going to be an iterative process. We’re climbing a learning curve, and dealing with a bit of a moving target. So we need to retain flexibility; but we need to lay a foundation for ultimately developing a regulatory approach that is comprehensive, allows for innovation, but also provides for public trust and dealing with real risks.

TR: What’s one of the first things that needs to be done?

RD: We absolutely need to have a better research strategy in place that says: here are the questions that need to be answered, and we will have answers to these within two years or three years, and we’re spending the money on the right things.

TR: Will fair regulation of a field as complex as nanotechnology be possible without a radical new approach?

RD: We’ve dealt with some pretty tough issues in regulation and legislation, and I don’t know if nano is so novel or so unique that it’s going to require a whole new approach. We understand the basics of assessing hazard. We understand the basics of assessing exposure and mitigating exposure. Those need to be tailored and adapted to the characteristics of nanomaterials, but I don’t know that we’re talking about anything much more radical than that.

1 comment. Share your thoughts »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me